Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the Dutch Research Council’s Stevin Prize - Seite 2
In addition to his role at the Netherlands Cancer Institute in Amsterdam, Dr. Schumacher is Professor of Immunotechnology at Leiden University Medical Center and a member of Oncode Institute, the virtual Dutch cancer research institute. He is the founder of four biotechnology companies focused on immuno-oncology, including most recently, the co-founding of Neogene Therapeutics which provides unique access to tumor-specific, TIL-derived TCRs for engineered T cell therapy in solid cancers. In addition to the Stevin Prize, Dr. Schumacher is a recipient of, among others, the Amsterdam Inventor Award, Queen Wilhelmina Cancer Research Award, San Salvatore Award, Meyenburg Cancer Research Award, and William B. Coley Award.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell
(AlloCAR T) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates
with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use
terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that
convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things: the ability to innovate in allogeneic cell therapy and advance the clinical development of investigational AlloCAR T therapies, and
the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with
the SEC, including without limitation in its Form 10-Q for the quarter ended March 31, 2020. Any forward-looking statements that are made in this press release speak only as of the date
of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press
release.
AlloCAR T is a trademark of Allogene Therapeutics, Inc.
Lesen Sie auch
Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com